These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36050598)

  • 1. Characteristics and outcomes of heart transplant recipients with a pretransplant history of malignancy.
    Youn JC; Kim D; Kim KA; Kim JJ; Kim IC; Lee HS; Choi JO; Jeon ES; Nishihara K; Kransdorf EP; Chang DH; Kittleson MM; Patel JK; Ramzy D; Esmailian F; Kobashigawa JA
    Am J Transplant; 2022 Dec; 22(12):2942-2950. PubMed ID: 36050598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Pretransplant Skin Cancer With Posttransplant Malignancy, Graft Failure and Death in Kidney Transplant Recipients.
    Kang W; Sampaio MS; Huang E; Bunnapradist S
    Transplantation; 2017 Jun; 101(6):1303-1309. PubMed ID: 27336396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric heart transplantation: 23-year single-center experience.
    Huebler M; Schubert S; Lehmkuhl HB; Weng Y; Miera O; Alexi-Meskishvili V; Berger F; Hetzer R
    Eur J Cardiothorac Surg; 2011 May; 39(5):e83-9. PubMed ID: 21354807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics, outcomes, and predictors of
    Youn JC; Kim D; Kim IC; Lee HS; Choi JO; Jeon ES; Nishihara K; Kransdorf EP; Chang DH; Kittleson MM; Patel JK; Ramzy D; Esmailian F; Kobashigawa JA
    Front Cardiovasc Med; 2022; 9():939275. PubMed ID: 36003907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo malignancy in heart transplant recipients: A single center experience in Japan.
    Kimura Y; Yanase M; Mochizuki H; Iwasaki K; Toda K; Matsuda S; Takenaka H; Kumai Y; Kuroda K; Nakajima S; Watanabe T; Ikura MM; Wada K; Matsumoto Y; Seguchi O; Fukushima S; Fujita T; Kobayashi J; Fukushima N
    J Cardiol; 2019 Mar; 73(3):255-261. PubMed ID: 30587457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De Novo Anti-HLA Antibodies After Heart Transplantation Are Associated With Adverse Events in the Long-term Follow-up of Cardiac Transplant Recipients.
    Solé-González E; Mirabet S; Brossa V; López-López L; Rivas-Lasarte M; Capellades-Olivella H; Ginel-Iglesias AJ; Martorell-Pons J; Roig E
    Transplant Proc; 2016 Nov; 48(9):3030-3032. PubMed ID: 27932139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early aspirin use and the development of cardiac allograft vasculopathy in pediatric heart transplant recipients: A pediatric heart transplant society analysis.
    D'Addese L; Cantor RS; Koehl D; Reardon L; Ameduri R; Bock M; Morrison A; White S; Wisotzkey B; Kirklin JK; Godown J
    J Heart Lung Transplant; 2023 Jan; 42(1):115-123. PubMed ID: 36328858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor-specific antibodies to human leukocyte antigens are associated with and precede antibodies to major histocompatibility complex class I-related chain A in antibody-mediated rejection and cardiac allograft vasculopathy after human cardiac transplantation.
    Nath DS; Angaswamy N; Basha HI; Phelan D; Moazami N; Ewald GA; Mohanakumar T
    Hum Immunol; 2010 Dec; 71(12):1191-6. PubMed ID: 20868717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mild acute cellular rejection and development of cardiac allograft vasculopathy assessed by intravascular ultrasound and coronary angiography in heart transplant recipients-a SCHEDULE trial substudy.
    Nelson LM; Andreassen AK; Arora S; Andersson B; Gude E; Eiskjaer H; Rådegran G; Dellgren G; Gullestad L; Gustafsson F
    Transpl Int; 2020 May; 33(5):517-528. PubMed ID: 31958178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of antibody-mediated rejection compared to acute cellular rejection after pediatric heart transplantation.
    Vaughn GR; Jorgensen NW; Law YM; Albers EL; Hong BJ; Friedland-Little JM; Kemna MS
    Pediatr Transplant; 2018 Feb; 22(1):. PubMed ID: 29222866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left ventricular global longitudinal strain predicts major adverse cardiac events and all-cause mortality in heart transplant patients.
    Clemmensen TS; Eiskjær H; Løgstrup BB; Ilkjær LB; Poulsen SH
    J Heart Lung Transplant; 2017 May; 36(5):567-576. PubMed ID: 28089194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart transplantation: 25 years' single-centre experience.
    Bruschi G; Colombo T; Oliva F; Botta L; Morici N; Cannata A; Vittori C; Turazza F; Garascia A; Pedrazzini G; Frigerio M; Martinelli L
    J Cardiovasc Med (Hagerstown); 2013 Sep; 14(9):637-47. PubMed ID: 23340045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy.
    Nath DS; Ilias Basha H; Tiriveedhi V; Alur C; Phelan D; Ewald GA; Moazami N; Mohanakumar T
    J Heart Lung Transplant; 2010 Nov; 29(11):1277-85. PubMed ID: 20615726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated ST2 levels are associated with antibody-mediated rejection in heart transplant recipients.
    Grupper A; AbouEzzeddine OF; Maleszewski JJ; Grupper A; Geske JR; Kremers WK; Kushwaha SS; Pereira NL
    Clin Transplant; 2018 Sep; 32(9):e13349. PubMed ID: 29998506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric recipient survival beyond 15 post-heart transplant years: a single-center experience.
    Copeland H; Razzouk A; Chinnock R; Deming D; Hasaniya N; Bailey L
    Ann Thorac Surg; 2014 Dec; 98(6):2145-50; discussion 2150-1. PubMed ID: 25443019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of third heart transplants in pediatric and young adult patients: analysis of the United Network for Organ Sharing database.
    Friedland-Little JM; Gajarski RJ; Yu S; Donohue JE; Zamberlan MC; Schumacher KR
    J Heart Lung Transplant; 2014 Sep; 33(9):917-23. PubMed ID: 24861821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex Related Differences in the Risk of Antibody-Mediated Rejection and Subsequent Allograft Vasculopathy Post-Heart Transplantation: A Single-Center Experience.
    Grupper A; Nestorovic EM; Daly RC; Milic NM; Joyce LD; Stulak JM; Joyce DL; Edwards BS; Pereira NL; Kushwaha SS
    Transplant Direct; 2016 Oct; 2(10):e106. PubMed ID: 27795988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cardiac allograft vasculopathy in heart and heart-lung transplantations: a 15-year retrospective study.
    Guihaire J; Mercier O; Flécher E; Aymami M; Fattal S; Chabanne C; Leroy Ladurie F; Lelong B; Cerrina J; Langanay T; Mussot S; Fabre D; De Latour B; Corbineau H; Verhoye JP; Dartevelle P; Leguerrier A; Fadel E
    J Heart Lung Transplant; 2014 Jun; 33(6):636-43. PubMed ID: 24630860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTor-inhibition within the first days after pediatric heart transplantation is a potentially safe option to prevent cardiac allograft vasculopathy.
    Kreienbaum H; Stiller B; Kubicki R; Bobrowski A; Kroll J; Fleck T
    Pediatr Transplant; 2024 Mar; 28(2):e14698. PubMed ID: 38433342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.